Incyte (INCY)
(Delayed Data from NSDQ)
$57.05 USD
0.00 (0.00%)
Updated May 15, 2024 04:00 PM ET
After-Market: $57.79 +0.74 (1.30%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.05 USD
0.00 (0.00%)
Updated May 15, 2024 04:00 PM ET
After-Market: $57.79 +0.74 (1.30%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Zacks News
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis
by Zacks Equity Research
FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in the United States.
AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS
by Zacks Equity Research
AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.
Lilly (LLY) Stock Up on Raised 2021 View, Upbeat 2022 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock rallies after it raises 2021 profit and sales outlook and provides an upbeat financial guidance for the next year.
AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label
by Zacks Equity Research
AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.
Why Is Incyte (INCY) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow
by Zacks Equity Research
Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Incyte (INCY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 55.26% and 8.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Incyte Corporation (INCY) Ahead of Earnings?
by Zacks Equity Research
Incyte Corporation (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
by Zacks Equity Research
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales
by Zacks Equity Research
Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.
Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib
by Zacks Equity Research
The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.
Incyte's (INCY) Going Gets Rough Despite Recent Approvals
by Zacks Equity Research
Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.
Xencor (XNCR) Inks Deal With J&J for B-Cell Malignancy Treatment
by Zacks Equity Research
Xencor (XNCR) partners will J&J (JNJ) to develop and commercialize bispecific antibody candidates against B-cell malignancy. Resultantly, the stock gains.
Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.
Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate
by Zacks Equity Research
Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.
Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD
by Zacks Equity Research
Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA
by Ekta Bagri
Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.
Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis
by Zacks Equity Research
Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.
AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.
Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate
by Zacks Equity Research
Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.
AbbVie (ABBV) Stock Down as FDA Issues New Warning for Rinvoq
by Zacks Equity Research
FDA requires a heart-risk warning on the label of AbbVie's (ABBV) JAK inhibitor medicine, Rinvoq.